Mitomycin therapy in gastric cancer

Area of Science:

• Oncology
• Gastrointestinal Oncology
• Medical Pharmacology

Background:

• Gastric adenocarcinoma is a leading cause of cancer mortality globally.
• Most patients are diagnosed with advanced-stage disease (III or IV), limiting surgical curability.
• Chemotherapy is a critical treatment modality for advanced gastric cancer.

Purpose of the Study:

• To review the efficacy and role of mitomycin in the treatment of gastric adenocarcinoma.
• To evaluate mitomycin's performance in various chemotherapy regimens, including single-agent and combination therapies.
• To discuss the potential of mitomycin in future gastric cancer treatment strategies.

Main Methods:

• Review of existing clinical trials and literature on mitomycin in gastrointestinal malignancies.
• Analysis of response rates, median survival, and toxicity profiles of mitomycin-based regimens.
• Comparison of mitomycin-containing regimens, such as FAM (5-fluorouracil/doxorubicin/mitomycin), with other treatment options.

Main Results:

• Intravenous mitomycin has shown response rates ranging from 24% to 63% in gastrointestinal malignancies.
• The FAM regimen (5-fluorouracil/doxorubicin/mitomycin) demonstrated a median survival of 29.5 weeks and lower toxicity compared to other doxorubicin regimens.
• Addition of semustine or leucovorin to FAM did not significantly improve response rates.

Conclusions:

• Mitomycin is an effective agent in treating gastric adenocarcinoma, particularly within combination chemotherapy regimens like FAM.
• The FAM regimen represents a standard treatment option, offering a balance of efficacy and safety.
• Intraperitoneal administration of mitomycin in Japan suggests potential for novel therapeutic approaches in gastric cancer treatment.